
BeyondSpring BYSI
$ 1.37
1.48%
Quarterly report 2025-Q3
added 02-21-2026
BeyondSpring Accounts Payables 2011-2026 | BYSI
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables BeyondSpring
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 295 K | 561 K | 1.08 M | 1.66 M | 2.22 M | 2.54 M | 9.59 M | 3.38 M | 444 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.59 M | 295 K | 2.42 M |
Quarterly Accounts Payables BeyondSpring
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 304 K | 266 K | 358 K | 295 K | - | - | - | - | - | - | - | 1.66 M | 2.13 M | 2.15 M | 1.57 M | 2.22 M | 2.19 M | 1.95 M | 5.14 M | 2.54 M | 1.95 M | 8.46 M | 8.97 M | 9.59 M | - | 2.8 M | 4.39 M | 3.38 M | 1.02 M | 2.03 M | 1.01 M | 444 K | - | - | - | 300 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 9.59 M | 266 K | 2.68 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
570 M | - | - | $ 866 M | ||
|
Apellis Pharmaceuticals
APLS
|
56.8 M | $ 20.7 | -1.24 % | $ 2.61 B | ||
|
Aptorum Group Limited
APM
|
3.24 M | $ 0.84 | 7.59 % | $ 4.58 M | ||
|
Axsome Therapeutics
AXSM
|
65.5 M | $ 166.38 | 1.52 % | $ 8.28 B | ||
|
Capricor Therapeutics
CAPR
|
183 K | $ 26.86 | -3.83 % | $ 719 M | ||
|
Codexis
CDXS
|
2.84 M | $ 1.02 | 0.99 % | $ 74.9 M | ||
|
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | ||
|
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | ||
|
CNS Pharmaceuticals
CNSP
|
1.98 M | $ 3.13 | -0.95 % | $ 1.2 M | ||
|
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | ||
|
Collegium Pharmaceutical
COLL
|
10.7 M | $ 41.6 | -0.17 % | $ 1.32 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
40.4 M | $ 35.97 | 0.76 % | $ 3.74 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
11.2 M | $ 23.88 | 3.47 % | $ 2.92 B | ||
|
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
3.18 M | $ 8.35 | -2.57 % | $ 36.1 M | ||
|
Curis
CRIS
|
3.02 M | $ 1.08 | -5.26 % | $ 6.81 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
22.6 M | $ 40.68 | -1.02 % | $ 3.83 B | ||
|
Corvus Pharmaceuticals
CRVS
|
1.52 M | $ 17.89 | -2.03 % | $ 859 M | ||
|
Champions Oncology
CSBR
|
4.25 M | $ 6.07 | 2.71 % | $ 82.9 M | ||
|
Citius Pharmaceuticals
CTXR
|
4.93 M | $ 0.72 | -2.3 % | $ 4.84 M | ||
|
CEL-SCI Corporation
CVM
|
1.45 M | $ 3.83 | -10.09 % | $ 244 M | ||
|
Daré Bioscience
DARE
|
1.46 M | $ 1.61 | -5.29 % | $ 13.7 M | ||
|
DBV Technologies S.A.
DBVT
|
22 M | $ 23.25 | 10.77 % | $ 2.26 B | ||
|
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
677 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | ||
|
Precision BioSciences
DTIL
|
2.97 M | $ 4.33 | 3.1 % | $ 16.6 M | ||
|
Agenus
AGEN
|
61.4 M | $ 3.34 | 0.3 % | $ 1.2 M | ||
|
Dyadic International
DYAI
|
656 K | $ 0.77 | -1.68 % | $ 22.2 M | ||
|
Ayala Pharmaceuticals
AYLA
|
4.08 M | - | - | $ 7.46 M | ||
|
Editas Medicine
EDIT
|
5.49 M | $ 2.15 | -2.27 % | $ 177 M | ||
|
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
18.4 M | $ 29.2 | -3.41 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
6.08 M | - | -9.65 % | $ 45.9 M | ||
|
Equillium
EQ
|
4.71 M | $ 1.92 | 5.49 % | $ 66.7 M |